Skip to main content

Table 2 Primary outcome

From: Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

  ARNI
(N = 87)
Standard treatment
(N = 100)
Crude HR
(95% CI),
p-value
Adjusted HR* (95% CI),
p-value
Primary composite outcome
 Mortality or hospitalization for heart failure 10 (11.5%) 28 (28.0%) 0.34 (0.15–0.80),
p = 0.013
0.32 (0.13–0.82),
p = 0.017
Component of composite outcome
 Mortality** 0 (0%) 4 (4.0%) p = 0.125
 Hospitalization for heart failure 10 (11.5%) 26 (26.0%) 0.31 (0.13–0.73),
p = 0.007
  1. ARNI = angiotensin receptor/ neprilysin inhibitor, HR = hazard ratio
  2. *Cox-regression analysis adjusted by age, BMI, dilated cardiomyopathy, chronic kidney disease, use of cardiac resynchronization therapy, use of ivabradine
  3. **Fisher Exact test